诺华的争议事件

品牌回应

• 召回 — Novartis

  Novartis made the recall on August 4.

来源摘录

• The batch that is being recalled has AV5913C on the packaging and include packages of 90 160-mg tablets with an expiration date of June 2027.

• The valsartan drug was made by Novartis under the brand name Diovan and has been recalled as it does not meet dissolution specifications.

• The US Food and Drug Administration has determined the notice as a Class II recall, which means exposure to the drug may lead to “temporary or medically reversible adverse health consequences.”

来源摘录

• Name of Product: Sandimmune® (cyclosporine capsules, USP) 100 mg soft gelatin capsules and Neoral® (cyclosporine capsules, USP) MODIFIED 100 mg soft gelatin capsules prescription drug blister packages

• Distributor: Novartis Pharmaceuticals Corporation, of East Hanover, N.J.

• WASHINGTON, March 18, 2020 /PRNewswire/ -- https://cpsc.gov/Recalls/2020/Novartis-Recalls-100-mg-Sandimmune-and-Neoral-Prescription-Drug-Blister-Packages-Due-to-Failure-to-Meet-ChildResistant-Packaging-Requirement-Risk-of-Poisoning

品牌回应

• 退款或补偿 — Novartis

  Novartis has agreed to pay $678 million to settle a civil fraud lawsuit.

来源摘录

• The U.S. government accused the Swiss drugmaker of illegally providing doctors with cash payments and other perks to induce them to prescribe its cardiovascular and diabetes drugs.

• Novartis has agreed to pay $678 million to settle a civil fraud lawsuit.

• The U.S. Department of Justice announced the settlement late on Wednesday to resolve charges that Novartis violated the federal False Claims Act and an anti-kickback statute.

品牌回应

• 道歉 — GSK

  In an affidavit, GSK's head of legal Navaneetha Dilipumakanth apologised for the company's conduct and admitted it had "fallen short of the standards expected of it under the Australian Consumer Law".

• 道歉 — GSK

  In an affidavit, GSK's head of legal Navaneetha Dilipumakanth apologised for the company's conduct

来源摘录

• GSK and Novartis admitted they had breached Australian consumer law with their marketing of Osteo Gel between 2012 and 2017.

• In an affidavit, GSK's head of legal Navaneetha Dilipumakanth apologised for the company's conduct and admitted it had "fallen short of the standards expected of it under the Australian Consumer Law".

• The parties also agreed on the question of penalties and Federal Court Justice Robert Bromwich today ordered GSK pay a fine of $1.5 million and Novartis pay $3 million.